Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Randomised clinical trials in critical care: past, present and future

    Research output: Contribution to journalReviewResearchpeer-review

  3. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hyperoxia and Antioxidants for Myocardial Injury in Noncardiac Surgery: A 2 × 2 Factorial, Blinded, Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Perioperative fluid administration and complications in emergency gastrointestinal surgery-an observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients.

METHODS: We searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language.

RESULTS: We included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95 % CI 0.88-1.03, I (2) = 0 %, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95 % Cl 0.88-1.03, I (2) = 0 %, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95 % CI 1.35-1.84, I (2) = 0 %, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance.

CONCLUSIONS: There is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding.

Original languageEnglish
JournalIntensive Care Medicine
Volume42
Issue number4
Pages (from-to)505-20
ISSN0342-4642
DOIs
Publication statusPublished - 9 Feb 2016

ID: 46255944